Ozempic-famed Novo Nordisk took over a $70 billion wipeout off its market value this week. Is this the beginning of a trend, ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Aggressive social media marketing by influencers has fuelled a surge in over-the-counter use of the diabetes and obesity ...

The Fed kept rates steady, as most economists had expected, but struck a more hawkish tone, causing a mid-afternoon stock sell-off.

FDA Commissioner Marty Makary spoke with Yahoo Finance about solving the food crisis, obesity crisis, and restoring trust in ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, patient investors could find opportunity as the stock falls.

Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) investors concerning the Company's possible violations of federal ...